替奈普酶治疗急性缺血性卒中的研究进展及展望

doi:10.3969/j.issn.1673-5765.2025.01.002

摘要/Abstract

摘要： 本文总结了替奈普酶治疗急性缺血性卒中的临床研究结果并展望了替奈普酶更广泛的临床应用和需求前景。目前的研究已经证实了在缺血性卒中发病4.5 h内，替奈普酶替代阿替普酶进行静脉溶栓治疗的实力。虽然在急性缺血性卒中的特殊人群和超再灌注时间窗治疗中，替奈普酶的有效性和安全性尚缺乏足够的循证医学证据，但目前已经开展了较多的相关研究，部分正在进行的研究将为上述患者的治疗提供更多依据。

关键词: 替奈普酶; 溶栓; 急性缺血性卒中

Abstract: This paper summarizes the clinical research results of tenecteplase in the treatment of acute ischemic stroke and looks forward to the broader clinical application and demand of tenecteplase. The current study has confirmed the strength of tenecteplase as a replacement for alteplase in intravenous thrombolysis within 4.5 hours of the onset of ischemic stroke. Although there is insufficient evidence-based medical evidence on the efficacy and safety of tenecteplase in the special population of acute ischemic stroke and treatment beyond the reperfusion time window, many related studies have been conducted to date. Some ongoing research will provide more evidence for the treatment of these patients.

Key words: Tenecteplase; Thrombolysis; Acute ischemic stroke

中图分类号:

徐露, 董漪, 董强. 替奈普酶治疗急性缺血性卒中的研究进展及展望[J]. 中国卒中杂志, 2025, 20(1): 20-25.

XU Lu, DONG Yi, DONG Qiang. Research Progress and Prospect of Tenecteplase in the Treatment of Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2025, 20(1): 20-25.

参考文献

[1] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志，2024，57（6）：523-559.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chin J Neurol，2024，57（6）：523-559.
[2] LOGALLO N，NOVOTNY V，ASSMUS J，et al. Tenecteplase versus alteplase for management of acute ischaemic stroke（NOR-TEST）：a phase 3，randomised，open-label，blinded endpoint trial[J]. Lancet Neurol，2017，16（10）：781-788.
[3] KVISTAD C E，NÆSS H，HELLEBERG B H，et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway（NOR-TEST 2，part A）：a phase 3，randomised，open-label，blinded endpoint，non-inferiority trial[J]. Lancet Neurol，2022，21（6）：511-519.
[4] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[5] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[6] MENG X，LI S Y，DAI H G，et al. Tenecteplase vs. alteplase for patients with acute ischemic stroke：the ORIGINAL randomized clinical trial[J]. JAMA，2024，332（17）：1437-1445.
[7] MUIR K W，FORD G A，FORD I，et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset（ATTEST-2）：a randomised，parallel group，open-label trial[J]. Lancet Neurol，2024，23（11）：1087-1096.
[8] PARSONS M W，YOGENDRAKUMAR V，CHURILOV L，et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke（TASTE）：a multicentre，randomised，controlled，phase 3 non-inferiority trial[J]. Lancet Neurol，2024，23（8）：775-786.
[9] BURGOS A M，SAVER J L. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke：meta-analysis of 5 randomized trials[J]. Stroke，2019，50（8）：2156-2162.
[10] WARACH S J，RANTA A，KIM J，et al. Symptomatic intracranial hemorrhage with tenecteplase vs. alteplase in patients with acute ischemic stroke[J]. JAMA Neurol，2023，80（7）：732-738.
[11] LIU Y，LU G Z，LI D，et al. Tenecteplase thrombolytic therapy for acute ischaemic stroke in China：a real-world，multicentre，retrospective，controlled study[J/OL]. Stroke Vasc Neurol，2024：003381[2024-12-10]. https://doi.org/10.1136/svn-2024-003381.
[12] YOGENDRAKUMAR V，CHURILOV L，MITCHELL P J，et al. Safety and efficacy of tenecteplase in older patients with large vessel occlusion：a pooled analysis of the EXTEND-IA TNK trials[J/OL]. Neurology，2022，98：e1292-12301[2024-10-09]. https://doi.org/10.1212/wnl.0000000000013302.
[13] WERF F V，RISTIĆ A D，AVERKOV O V，et al. STREAM-2：Half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction：a randomized，open-label trial[J]. Circulation，2023，148（9）：753-764.
[14] PARSONS M，SPRATT N，BIVARD A，et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2012，366（12）：1099-1107.
[15] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-1582.
[16] MARNAT G，LAPERGUE B，GORY B，et al. Intravenous thrombolysis with tenecteplase versus alteplase combined with endovascular treatment of anterior circulation tandem occlusions：a pooled analysis of ETIS and TETRIS[J]. Eur Stroke J，2024，9（1）：124-134.
[17] KATSANOS A H，SAFOURIS A，SARRAJ A，et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions：systematic review and meta-analysis[J]. Stroke，2021，52（1）：308-312.
[18] BALA F，SINGH N，IGNACIO K，et al. Tenecteplase versus alteplase in medium vessel occlusion ischemic stroke：a secondary analysis of the alteplase compared to tenecteplase randomized trial[J]. J Stroke，2024，26（2）：280-289.
[19] ZHAO Z A，QIU J，WANG L，et al. Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis：the BRETIS-TNK trial[J/OL]. Front Neurol，2023，14：1155269[2024-12-09]. https://doi.org/10.3389/fneur.2023.1155269.
[20] COUTTS S B，DUBUC V，MANDZIA J，et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion[J]. Stroke，2015，46（3）：769-774.
[21] COUTTS S B，ANKOLEKAR S，APPIREDDY R，et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion（TEMPO-2）：a randomised，open label，phase 3 superiority trial[J]. Lancet，2024，403（10444）：2597-2605.
[22] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.
[23] THOMALLA G，SIMONSEN C Z，BOUTITIE F，et al. MRI-guided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med，2018，379（7）：611-622.
[24] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（7）：701-711.
[25] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[26] ROALDSEN M B，ELTOFT A，WILSGAARD T，et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT（TWIST）：a multicentre，open-label，randomised controlled trial[J]. Lancet Neurol，2023，22（2）：117-126.
[27] WANG L，DAI Y J，CUI Y，et al. Intravenous tenecteplase for acute ischemic stroke within 4.5-24 hours of onset（ROSE-TNK）：a phase 2，randomized，multicenter study[J]. J Stroke，2023，25（3）：371-377.
[28] CHENG X，HONG L，CHURILOV L，et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection：the umbrella phase Ⅱa CHABLIS-T randomised clinical trial[J]. Stroke Vasc Neurol，2024，9（5）：551-559.